Skip to main content
SpringerLink
Log in

Trastuzumab in Combination with FOLFIRI in Patients with Advanced HER2-Positive Gastro-Esophageal Adenocarcinoma: A Retrospective Multicenter AGEO Study

  • Short Communication
  • Published:
Targeted Oncology Aims and scope Submit manuscript

Abstract

Background

Trastuzumab with fluoropyrimidine and cisplatin is the standard first-line treatment in patients with HER2-positive advanced gastro-esophageal adenocarcinoma. However, there are no safety and efficacy data of trastuzumab with FOLFIRI.

Objective

To evaluate safety and efficacy of FOLFIRI plus trastuzumab in patients with HER2-positive advanced gastro-esophageal adenocarcinoma.

Patients and Methods

This retrospective multicenter study included all consecutive patients with HER2-positive advanced gastro-esophageal adenocarcinoma treated with FOLFIRI plus trastuzumab between 2012 and 2015.

Results

A total of 33 patients (median age, 60.3; performance status 0–1, 78.8%) with HER2-positive advanced gastro-esophageal adenocarcinoma treated with FOLFIRI plus trastuzumab in first (n = 3), second (n = 20) or third (n = 10) line of chemotherapy were included. There was one case of a severe non-hematological adverse event corresponding to a left ventricular systolic dysfunction. The most common hematological grade 3 or 4 adverse events were neutropenia (12.9%) and thrombocytopenia (6.4%). There was no febrile neutropenia. For patients treated with FOLFIRI plus trastuzumab in second-line chemotherapy, the median overall survival was 9.5 months.

Conclusions

This is the first western population-based study of FOLFIRI plus trastuzumab reporting a satisfactory safety profile and a potential efficacy in advanced HER2-positive gastric cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Junttila TT, Akita RW, Parsons K et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell. 2009;15:429–40.

    Article  CAS  PubMed  Google Scholar 

  2. Boku N. HER2-positive gastric cancer. Gastric Cancer. 2014;17:1–12.

    Article  CAS  PubMed  Google Scholar 

  3. Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.

    Article  CAS  PubMed  Google Scholar 

  4. Smyth EC, Verheij M, Allum W et al. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v38–49.

    Article  CAS  PubMed  Google Scholar 

  5. Bennouna J, Sastre J, Arnold D et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013;14:29–37.

    Article  CAS  PubMed  Google Scholar 

  6. von Minckwitz G, du Bois A, Schmidt M et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol. 2009;27:1999–2006.

    Article  Google Scholar 

  7. Guimbaud R, Louvet C, Ries P et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (federation francophone de Cancerologie digestive, federation Nationale des Centres de Lutte Contre le cancer, and Groupe Cooperateur Multidisciplinaire en Oncologie) study. J Clin Oncol. 2014;32:3520–6.

    Article  CAS  PubMed  Google Scholar 

  8. Thuss-Patience PC, Kretzschmar A, Bichev D et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer—a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011;47:2306–14.

    Article  CAS  PubMed  Google Scholar 

  9. Kang JH, Lee SI, Lim DH et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 2012;30:1513–8.

    Article  CAS  PubMed  Google Scholar 

  10. Yamade M, Sugimoto M, Nishino M et al. Trastuzumab has opposing effects on SN-38-induced double-strand breaks and cytotoxicity in HER2-positive gastric cancer cells depending on administration sequence. Anticancer Res. 2012;32:105–14.

    CAS  PubMed  Google Scholar 

  11. Fujimoto-Ouchi K, Sekiguchi F, Yasuno H et al. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol. 2007;59:795–805.

    Article  CAS  PubMed  Google Scholar 

  12. de Gramont A, Bosset JF, Milan C et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol. 1997;15:808–15.

    Article  PubMed  Google Scholar 

  13. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.

    Article  CAS  PubMed  Google Scholar 

  14. Palle J, Tougeron D, Pozet A et al. Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study. J Clin Oncol. 2017;35(4_suppl):94.

    Article  Google Scholar 

  15. Weissinger F, Reymond M, Dumke K et al. Successful treatment of a patient with HER2-positive metastatic gastric cancer with third-line combination therapy with irinotecan, 5-fluorouracil, leucovorin and trastuzumab (FOLFIRI-T). Onkologie. 2011;34:548–51.

    Article  PubMed  Google Scholar 

  16. Dubreuil O, Zaanan A, Pellerin O et al. Trastuzumab re-introduction with FOLFIRI for treatment of HER2 Overexpression-advanced gastric Adenocarcinoma following failure of other Trastuzumab-based chemotherapy regimens. Case Rep Clin Med. 2015;4:131–6.

    Article  Google Scholar 

  17. Sun J, Pan SY, Chen QQ et al. Efficacy of trsatuzumab (Herceptin) combined with FOLFIRI regimen in the treatment of HER2-positive advanced gastric cancer. Nan Fang Yi Ke Da Xue Xue Bao. 2011;31:1458–60.

    PubMed  Google Scholar 

  18. Sugimoto N, Sakai D, Kawada J et al. A phase II trial of trastuzumab combined with irinotecan in patients with advanced HER2-positive chemo-refractory gastric cancer: OGSG1203 (HERBIS-5). J Clin Oncol. 2016;34(15_suppl):e15546-e.

    Google Scholar 

  19. Li Q, Jiang H, Li H et al. Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study. Oncotarget. 2016;7:50656–65.

  20. Thuss-Patience PC, Shah MA, Ohtsu A et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol. 2017;18:640–53.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank all the physicians and the clinical research technicians of the AGEO centers for their participation and assistance.

Author information

Authors and Affiliations

  1. Department of Gastroenterology and Digestive Oncology, European Georges Pompidou Hospital, Assistance Publique-Hôpitaux de Paris, 20 rue Leblanc, 75015, Paris, France

    Aziz Zaanan & Julien Taieb

  2. Paris Descartes University, Sorbonne Paris Cité, Paris, France

    Aziz Zaanan & Julien Taieb

  3. Department of Medical Oncology, Saint Antoine Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France

    Juliette Palle

  4. Department of Gastroenterology and Digestive Oncology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France

    Emilie Soularue

  5. Department of Cancer Medicine, Gustave Roussy Institute, Villejuif, France

    Florence Leroy

  6. Department of Oncology, Oncology Federation of Essonne, Essonne, France

    Samy Louafi

  7. Department of Gastroenterology, Poitiers University Hospital, Poitiers, France

    David Tougeron

  8. Department of Gastroenterology and Digestive Oncology, Rennes University Hospital, Rennes, France

    Sylvain Manfredi

  9. Department of Gastroenterology and Digestive Oncology, Jean Mermoz Hospital, Lyon, France

    Pascal Artru

  10. Methodology and Quality of Life in Oncology Unit, INSERM UMR 1098, Besançon University Hospital, Besançon, France

    Astrid Pozet

Authors
  1. Aziz Zaanan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Juliette Palle
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Emilie Soularue
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Florence Leroy
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Samy Louafi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. David Tougeron
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sylvain Manfredi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Pascal Artru
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Astrid Pozet
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Julien Taieb
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aziz Zaanan.

Ethics declarations

Funding

None.

Conflict of Interest

Dr. Zaanan has participated in consulting or/and advisory boards for Merck, Amgen, Roche, Sanofi and Lilly; Dr. Taieb has participated in consulting or/and advisory boards for Roche, Sanofi, Merck, Amgen, Baxalta, Celgene, Lilly, Servier, Sirtex.

The remaining authors declare no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zaanan, A., Palle, J., Soularue, E. et al. Trastuzumab in Combination with FOLFIRI in Patients with Advanced HER2-Positive Gastro-Esophageal Adenocarcinoma: A Retrospective Multicenter AGEO Study. Targ Oncol 13, 107–112 (2018). https://doi.org/10.1007/s11523-017-0531-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11523-017-0531-4

Search

Navigation